|
| Status |
Public on Jun 01, 2023 |
| Title |
LSD1 inhibition disrupts super-enhancer activities in CRPC [RNA-seq] |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by high throughput sequencing
|
| Summary |
Our studies revealed a novel oncogenic function of LSD1 in driving PCa progression by activating MYC signaling and mediating CRPC SEs activities, cotargeting LSD1 and BRD4 achieved significant synergistic effects in repressing CRPC tumor growth
|
| |
|
| Overall design |
CRPC xenograft models were treated with LSD1 inhibitor and BET inhibitor alone or in combination (LSD1 inhibitor with lower dosage). All RNA-seq samples contain replications.
|
| |
|
| Contributor(s) |
Liu M, Li M, Han W, Gao S, Cai C |
| Citation(s) |
36877164 |
| Submission date |
Jul 27, 2022 |
| Last update date |
Jun 01, 2023 |
| Contact name |
Changmeng Cai |
| E-mail(s) |
changmeng.cai@umb.edu
|
| Organization name |
University of Massachusetts Boston
|
| Street address |
100 William T Morrissey Blvd
|
| City |
Boston |
| State/province |
MA |
| ZIP/Postal code |
02125 |
| Country |
USA |
| |
|
| Platforms (2) |
| GPL16791 |
Illumina HiSeq 2500 (Homo sapiens) |
| GPL30173 |
NextSeq 2000 (Homo sapiens) |
|
| Samples (54)
|
|
| This SubSeries is part of SuperSeries: |
| GSE209889 |
LSD1 inhibition disrupts super-enhancer activities in CRPC |
|
| Relations |
| BioProject |
PRJNA862884 |
Less...
More...